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A perspective adsorptive method to minimize systemic toxic effects of chemotherapy is enterosorption (ES). However, the capa-
bilities of this method are far from being completely studied. The question remains opened — should ES be initiated in the first 
hours on completing cytostatic infusion without the risk of their anticancer activity to be decreased. Aim: to analyze ES influence 
on anticancer activity and toxic reactions of cisplatin (CP) upon the use of carbon enterosorbent in 1 h after intravenous adminis-
tration of cytostatic. Methods: CP at the dose of 1 mg/kg body weigh (BW) was administered to Guerin carcinoma-bearing rats 
each second day for two weeks. Enterosorbents on the basis of highly activated carbon fibers were administered by per os daily 
1 h after CP injection. 3 days after the last CP administration the rats were weighted and blood under ether narcosis has been 
taken for biochemical examination. Tumors and innate organs were isolated, weighted, and fixed in 4% buffered formalin for 
morphologic examination. Results: In rats administered with CP at the background of ES, BW loss was in 1.6 times lower than 
in animals after CP session. Relative kidney weight in CP-treated rats was 33.9% higher than in normal ones (p ≤ 0.05). No sig-
nificant differences were detected between relative kidney weights in the CP + ES-treated and intact animals. Introduction of ES al-
lowed prevent an 30% increase of creatinin content observed in blood plasma after CP treatment (р ≤ 0.05). Urea content was 
1.7 times lower in blood plasma of CP + ES-treated rats than after CP treatment. CP caused significant toxic injuries in kidneys, 
liver, and spleen tissues. Morphologic structure of organs in rats treated with CP at the background of ES was affected at much 
lower degree. In tumors, large areas of newly formed connective tissue and blood vessels have been fixed after the CP+ES action 
instead of large necrotic area observed after CP treatment. ES caused insignificant suppression of Guerin carcinoma growth and 
had additional impact to inhibitory action of CP. Conclusion: Active carbon enterosorbents which are administrated just 1 h after 
CP administration possesses detoxicating potential sufficient for significant elimination of toxic effect of the cytostatic at the 
background of complete preservation of its antitumor activity.
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The search for way to minimize systemic toxic effects 
of chemotherapy without the decrease of its anticancer 
activity is still actual. A special place in this problem 
solving is occupied by the methods of sorption therapy 
the possibilities of which are being constantly expanded 
due to the development of new effective sorbents of me-
dicinal purposes and original approaches for their use.
After massive chemotherapy accompanied with 
an expressed endogenous intoxication syndrome and 
cytostatic-dependent myelodepression, the method 
of hemosorption (HS) allows significantly alleviate 
these complications and thereby provide the possibility 
to continue the therapy by radical schemes [1]. In such 
situations the use of Hemosorbents Granulated Deli-
ganding (HSGD) developed in R.E. Kavetsky Institute 
of Experimental Pathology, Oncology and Radiobio-
logy of NAS of Ukraine (IEPOR) for effective removal 
of hydrophobic toxic metabolites strongly bound with 
blood plasma proteins (nonconjugated bilirubin, free 
fatty acids, phenols, bile acids, mercaptanes, a number 
of uraemic toxins) during HS procedure allows achieve 
qualitatively new therapeutic effects related to deep pu-
rification of transport proteins and blood cell membranes 
in patients with myocarditis, hepatitis and renal failure 
caused by cytostatic therapy [2, 3]. 
HS method provides unique possibilities for control 
of local and systemic pharmacokinetics of anticancer 
preparations. Therapeutically significant differences 
between the concentrations of anticancer prepara-
tions in the tumor and the most vulnerable organs are 
achieved in the first variant via selective intraarterial 
administration of high doses of cytostatics with the 
following sorption purification of blood which outflows 
from an affected organ [4–7]. 
Sorption system on the basis of highly active hemo-
sorbents of HSGD type performs deep blood purifica-
tion from protein bound compounds including the large 
majority of anticancer preparations, and is capable 
to provide a safe sorption barrier that limits anticancer 
agent entering into systemic circulation. Thus, such 
approach allows regional introduction of high doses 
of cytostatics into the tumor with the decreased risk 
of systemic toxic effects. To increase the efficacy 
of removal from blood of cisplatin (CP) excess during 
the control of its local pharmacokinetics, one would 
sequentially introduce sorption column and dialyza-
tor into extracorporeal circuit [8]. The other method 
proposed is related to the control of systemic pharma-
cokinetics and make unneedful the collection of blood 
enriched with chemopreparation excess directly from 
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venous collectors of separate organ or tumor lesion, into 
which intraarterial catheter for cytostatic administra-
tion is applied. Instead of this blood is taken with high 
speed (from 500 ml/min to 1 ml/min and more) from 
any appropriate vasculature point and is returned into 
systemic circulation after massive sorption purification 
providing removal not less than 95% of chemoprepara-
tion. This variant also allows provide effective defence 
of vital organs from the action of high doses of cytostatic 
drugs [9]. One should mention that local scheme as well 
could provide the control of systemic pharmacokinetics 
of anticancer preparation, however just in a case when 
its concentration on column entry is lower that sys-
temic concentration supported by incomplete isolation 
of regional circle. In both mentioned cases the action 
of HS is not limited by its effect on the local and systemic 
concentration of anticancer drugs the large majority 
of which are related to radiomimetics, i.e., chemical 
compounds simulating the action of penetrating radia-
tion. That’s why it is reasonable to mention our previous 
results on the use of hemocarboperfusion method 
in a treatment of acute radiation sickness; then blood 
purification in dogs at the terms of 2 to 24 h after their 
homogenous irradiation at minimal absolutely lethal 
dose of 5.25 Gy has allowed achieve 65–70% animal 
survival at the background of an expressed myelopro-
tective effect [10]. It could not be excluded that such 
effect of HS could be true also for cytostatic therapy 
as far as for anticancer cytostatic pharmacokinetic con-
trol, but sorption purification of blood is performed not 
after accomplished radiation injury as in a case of early 
treatment of acute radiation sickness, but strictly during 
the primary action of radiomimetic agent. 
As a perspective method to fight endotoxicosis 
caused by systemic toxicity of anticancer cytostatics, 
one could consider enterosorption (ES), which efficacy 
has been initially proven by the results of experimental 
studies with the use of animals bearing transplanted 
tumors [11–13].
In the frame of study of ES effect toward myelotoxic-
ity of anticancer preparations, there have been shown 
that ES performed in Guerin carcinoma-bearing rats 
after treatment with cyclophosphamide and methotrex-
ate, has demonstrated an expressed myeloprotective 
effect toward all main bone marrow cell elements [13]. 
In Shvets erythromyelosis-bearing rats treated with 
carminomycine the myelocaryocyte and peripheral 
granulocyte counts were two and three times lower, 
respectively, that these in animals that were treated 
with carbon enterosorbents after antibiotic treatment 
[13]. Along with this ES alone demonstrates insig-
nificant suppressing effect toward transplanted tumor 
growth and elongates life time of animals treated with 
cytostatics compared to animals which are not treated 
with ES. In patients with Hodgkin’s lymphoma two-week 
ES course after intense chemoradiotherapy allowed 
reduce leukopenia duration by 1.5 times [14].
ES efficacy has been successfully applied in pa-
tients with malignant breast tumors and large bowel 
cancer at the post-operative period [15]. Two-weeks 
administration of carbon-mineral sorbent SCMS-1 with 
immobilized metronidazole which has been initiated 
a day after beginning of chemotherapy course, pre-
vented the development of expressed leukopenia and 
thrombocytopenia, elevation of urea and bilirubin con-
tents, aspartate aminotransferase (AST) and alanine 
aminotransferase (ALT) levels in blood plasma, and 
also decreased an intensity of clinical intoxication 
symptoms — nausea and vomiting. 
An important step in ES development was done 
by creation of moist boluses or granules formed from 
carbon fibers or micronized carbon particles with the 
use of water as a binder (Carboline, IEPOR production, 
Ukraine). Such technology provides total preservation 
of adsorptive properties of the sorbent and improves 
the kinetic parameters of adsorption. Also, the washed 
down preparation is immediately dispersed in oral cavity 
and is swallowed easily what is of special importance 
in the patients with increased vomiting activity. An ef-
ficacy of the use of carbon enterosorbent Carboline for 
prophylaxis of acute and delayed emetogenic toxicity 
of cytostatics has been demonstrated in patients with 
breast and lung cancer and Hodgkin’s disease [16]. 
Carboline at the dose of 15 tablets daily for 5 days before 
and 5 days after polychemotherapy session (ES is not 
indicated at the day of cytostatic administration) allows 
prevent severe toxic reactions caused by polychemo-
therapy which includes platinum group preparations, 
and by 4 times increases the number of patients without 
toxic reaction caused by platinate-free polychemo-
therapy. Delayed emetogenic toxicity characteristic 
nearly for half of the patients, has been observed just 
in 5% of the patients treated with ES.
So, the results of experimental studies and the 
data of clinical observations support an expediency 
of ES introduction into the complex of measures di-
rected on prophylaxis and minimization of systemic 
toxic effects of anticancer preparations. However, the 
capabilities of this method are far from being completely 
studied yet. In particular, the question remains — should 
ES be initiated in the first hours on completing cytostatic 
perfusion without the risk of decreasing the anticancer 
activity of the preparation. Therefore, the task of our 
experimental studies was to analyze ES influence on an-
ticancer activity of CP and toxic reactions upon the use 
of carbon enterosorbent in 1 h after intravenous admin-
istration of cytostatic characterized by quick clearance 
from blood via glomerular excretion [17]. According 
to our earlier results (unpublished data), CP concen-
tration in blood serum of Guerin carcinoma-bearing 
rats 5 min after intravenous administration of CP was 
equal to 24.5% of injected dose and was not higher 
than 3 and 0.9% in 1 and 24 h respectively. Such phar-
macokinetics of the cytostatic has been described for 
athymic mice bearing subcutaneous A2780 cell ovarian 
xenografts [18]. 
MATERIALS AND METHODS
Animals and experimental design. The stu-
dies were carried out on white inbred rats weighting 
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200 ± 20 g from the IEPOR vivarium. All animals pro-
cedures were carried out according to the rules and 
requirements of local Ethic Committee of IEPOR. Guerin 
carcinoma Т8 was transplanted subcutaneously in the 
left femur of animals. When tumor volume reached ap-
proximately 0.5 cm3 animals were randomly distributed 
according to their tumor volume into 4 groups: 1 — 
intact Guerin carcinoma-bearing rats (tumor) (n = 7); 
2 — Guerin carcinoma-bearing rats treated with ES 
(tumor + ES) (n = 8); 3 — with CP (tumor + CP) (n = 8); 
and 4 — with CP and ES (tumor + CP + ES) (n = 8). 
Control group consisted of 6 normal rats.
CP (Veropharm, Russia) has been injected each al-
ternate day in tail vein at the dose of 1.0 mg/1 kg body 
weight (BW) for 2 weeks. 
As enterosorbent, Carboline on the basis of highly 
activated fibrous carbon materials (Ukraine) was used. 
The fibers at the quantity of 0.65 g/1 kg BW as a sus-
pension in 2 ml of distilled water were introduced with 
the use of tube into rat stomach 1 h after CP adminis-
tration. Rats treated with CP only were introduced with 
2 ml of distilled water without the sorbent. Animals 
treated with enterosorbents received 0.5 ml of physi-
ologic solution instead of CP. 
Tumor volume was determined by three orthogonal 
diameters (а, b, c) according to the prolate ellipsoid 
formula: V = 0.52 (a×b×c). To characterize the dynamic 
tumor growth we have used K coefficient determined 
as the ratio between tumor volume at the given moment 
and tumor volume at the moment of the first CP injection. 
Three days after the last administration of the 
preparations the rats were weighted and blood under 
ether narcosis has been taken from vena cava inferior. 
Tumors and innate organs (lever, kidney, spleens) 
were isolated, washed with cold physiologic solution, 
weighted, and fixed in 4% buffered formalin.
The loss of BW was calculated using the following 
formula: BW loss (%) = (BW at the 1st day of CP in-
jection — BW at the 3rd day after last CP injection) 
x100/ BW at the first day of CP injection. 
Plasma concentrations of creatinin, urea, urinary 
acid, AST and ALT were analyzed at the clinical labora-
tory using a Clinical System (Beckman, CA). 
The statistical significance of the differences 
between mean values was assessed by the Stu-
dent’s t-test.
Morphology examination. Fixed in formalin 
tissues of organs and tumors were sectioned, de-
hydrated in 70% ethanol and paraffin embedded 
according to routine technique. Serial 5 μm sections 
were stained with hematoxylin and eosin, examined 
by light microscopy.
RESULTS AND DISCUSSION
The main task of our study was to analyze ES ef-
fects toward systemic toxic CP reactions in Guerin 
carcinoma beagin rats treated with enterosorbent 
1 h after intravenous administration of the cytostatic. 
The decrease of animal BW could serve as an indica-
tive criterion of endotoxicosis caused by toxic effects 
of the cytostatic and in part — by tumor growth [19]. 
Before CP administration, the Guerin carcinoma-
bearing rat BW was recorded. No significant differences 
were detected between the intact tumor, tumor+ES, 
tumor+CP, tumor+CP+ES groups: 249.8±22.4; 
246.2±19.4; 254.4±19.0; 242.6±14.1 g respectively. 
In the process of tumor development animal BW in intact 
tumor group decreased by 9.4±4.1% versus 7.4±3.6% 
in tumor+ES group (Table 1). After CP session the animal 
BW loss was 13.1±8.7%. Introduction of ES allowed de-
crease BW loss by 1.6 times. In tumour-bearing animals 
there has been recorded insignificant elevation of rela-
tive kidney weight (total organ weight/BW) while in rats 
treated with CP this index was 33.9% (p≤0.05) higher 
than in normal animals. In rats treated with CP+ES rela-
tive kidney weight didn’t differ significantly from respec-
tive value in control group. An increase of relative kidney 
weight by 1.5 times along with alterations in some bio-
chemical indexes and glomerular and tubular disruption 
has been observed in Guerin carcinoma-bearing rats 
upon single intraperitoneal administration of CP at the 
dose of 8 mg/kg [20]. Kidney hypertrophy is among 
manifestations of compensatory reaction in response 
to nephrotoxic agent action and is caused by adaptive 
increase of the size of remaining functional nephrones 
in which filtration rate and reabsorption of water-soluble 
compounds is being increased [21].
Table 1. Influence of ES on toxic reactions caused by Guerin carcinoma 
growth and cisplatin administration
Index
Groups 
Normal 
rats
Guerin carcinoma-bearing rats
Intact ES CP CP + ES
BW loss, % 9.4±4.1 7.4±3.6 13.1±8.7 8.3±3.7
Kidney weight/BW 6.2±1.3 6.8±0.8 6.3±0.7 8.3±1.7* 7.8±1.0
Liver weight /BW 44,0±5.1 51.2±8.2 44.5±6.3 48.7±3.1 43.8±6.2
Spleen weight/BW 5.8±1.0 9.5±2.9 9.3±1.7 5.0±0.9 4.2±0.7
Blood plasma creat-
inin content, mMol/l
61.9±5.7 71.0±9.7 58.4±11 80.3±9.0* 67.7±9.2
Blood plasma uric 
acid content, mMol/l
118±17.8 114±15.6 122±10.4 102±11.9 85±7.9
Blood plasma urea 
content, mMol/l
8.9±1.1 9.3±0.9 10.4±1.2 11.7±1.6 10.5±1.2
Blood plasma ALT, U/l 65±17 64±11 61±9 76±13 59±11
Blood plasma AST, U/l 135±19 - - 212±16* 143±18
* Difference is significant compared to the normal rats (p ≤ 0.050). 
After CP treatment insignificant increase of relative 
weights of liver and spleen in tumor + CP and tumor + 
CP + ES groups has been registered (Table 1), and 
more expressed one — in intact Guerin carcinoma-
bearing rats. ES has been causing normalizing effect 
on relative liver weight, but had no effect on spleen 
hyperplasia (tumor + ES group).
Blood plasma level of creatinin is a standard 
marker of glomerular disruption [20, 21]. Creatinin 
content which was practically equal in blood plasma 
of tumor-bearing rats and intact animals, has been 
elevated by 30% after CP session (р ≤ 0.05). Introduc-
tion of ES allowed prevent an increase of this index. 
After CP session there has been registered an elevation 
of urea content in blood plasma by 31%, while after 
combined treatment with CP + ES — by 17.9%. Uric acid 
content in blood plasma of rats from these groups stood 
within values of intact animals. AST level in rats treated 
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with CP was higher by 1.4 fold, and in animals treated 
with CP+ES was equal to that in intact control. No sig-
nificant differences in ALT levels have been recorded. 
The observed tendencies evidencing on modifying 
effect of ES on systemic CP toxicity, have found new 
confirmation during comparative analysis of alterations 
of histological structure of innate organs of rats upon 
tumour growth and CP or CP + ES treatment.
Morphological study of liver tissues of Guerin 
carcinoma-bearing rats has revealed the disruption 
of beam structure and dystrophy of hepatocytes, 
increased number of Kupffer cells and their sizes, 
and the presence of phagocytized cell debris in their 
cytoplasm (Fig. 1 a). Enlargement of sinusoids and ac-
cumulation of erythrocytes inside them could evidence 
on toxic effect of growing tumor on cell membranes 
of hepatocytes and endothelial cells. In kidney tis-
sue there has been observed an expressed tubular 
cell dystrophy, formation of lumen and decreased 
cell element numbers in glomerulus which in some 
glomerulus are represented just by ‘naked’ nuclei 
(Fig. 1 b). In the majority of glomerulus one could 
observe haemorrhages of various degree, in tubular 
lumen — small lesions of haemorrhages and hyaline 
inclusions. Morphological structure of spleen was 
characterized by increased number of lymphoid fol-
licles, some of them contained secondary germinal 
centers with blast elements, and rarely — significant 
amounts of macrophages (Fig. 1 c). 
At the background of ES the morphological chan-
ges in innate organ structure caused by growing 
tumour have been expressed at significantly lower 
level (Figс. 2 a–c). In some animals the morphological 
picture was close to normal one. 
Upon CP action the degree of toxic damage of in-
nate organ tissues drastically decreased. Morphologic 
structure of liver tissue is notably disrupted, large ne-
crosis area could be noticed. Hepatocytes are mostly 
in necrobiosis state. The rest of them have patterns 
of dystrophy (Fig. 3 a). Also, in liver cells there were 
observed “naked” nuclei, cell shadows, and empty 
cytoplasm. One could see small haemorrhages be-
tween hepatocyte cords and hyalinization of some 
vessels. CP caused notable disruption in renal tissue 
structure, alteration of anatomic region of glomerulus 
location which contained lower numbers of functional 
cells (Fig. 3 b). There have been recorded dystrophic 
changes practically in all functional cell elements, 
tubular necrosis, destruction of glomerules and forma-
tion of large lumens between tubules. In spleen tissue 
there was observed the formation of large secondary 
germinal centers, devastation of cells in marginal zone 
of spleen, erythrocyte destruction in red pulpa with 
appearance of small haemorrhages (Fig. 3 c). 
Microscopic picture of innate organ tissues of rats 
treated with CP and carbon enterosorbents is com-
pletely different: their morphological structure is af-
fected at significantly lower degree however, it varies 
between some animals (Fig. 4 a–c). 
In one rat liver structure is completely normal. 
In other animals hepatocytes possessed the patterns 
of dystrophy of different degree. However, in this cases 
around vessels there has been detected an appear-
ance of hepatocytes possessing more basophilic cyto-
plasm and dense nucleus (so called dark hepatocytes) 
which represent young liver cells that replace dead 
ones; this fact points on improvement of functional 
state of liver. In kidney tissues toxic disruption is ex-
pressed at lower level. There were no erythrocytes and 
hae morrhages in glomerules, and high cellularity has 
been registered. In tubular lumen there was detected 
a
b
c
Fig. 1. Morphological structure of innate organs in Guerin 
carcinoma-bearing rats (х 200): a — disruption of beam struc-
ture and dystrophy of hepatocytes in liver; b — haemorrhages 
in glomerules and hyalinosis in renal tubules; c — secondary 
germinal centers with blast elements in spleen 
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significantly lower numbers of erythrocytes, haemor-
rhages were rare enough. The large majority of cells 
in tubules are of normal morphological structure, the 
quantity of lumens between tubules and their sizes 
were lower. In one animal kidney structure was practi-
cally equal to that in healthy rats. Characteristic pattern 
of spleen was the prevalence of lymphoid follicles with 
extended marginal zone over red pulpa. 
Thus, daily administration of carbon enterosor-
bents results in significant suppression of systemic 
toxic reactions of CP. The obtained result could 
be of great practical importance, however, only in the 
case if ES doesn’t influence anticancer effect of the 
cytostatic. That’s why at the next stage of our research 
we have analyzed this issue.
An analysis of Guerin carcinoma growth in the groups 
of rats treated with the enterosorbent or CP alone 
or in combination has shown that daily administration 
of enterosorbent caused insignificant tumor growth 
inhibition and insignificant enhancement of CP inhibiting 
action (Fig. 5). On day 22 after tumor cell transplanta-
a
b
c
Fig. 2. Morphological structure of innate organs in Guerin 
carcinoma-bearing rats after ES treatment (х 200): a — liver; 
b — kidneys; c — spleen 
a
b
c
Fig. 3. Morphological structure of innate organs in Guerin 
carcinoma-bearing rats upon CP treatment: a — disruption 
of liver tissue structure, regions of necrobiosis, appearance 
of naked nuclei and empty cytoplasm (х200); b — dystrophy 
of functional renal cell elements, tubular necrosis, glomerular 
destruction and formation of large lumens between the tubules 
(х200); c — devastation of cells in marginal zone of spleen, 
erythrocyte destruction in red pulpa with appearance of moder-
ate haemorrhages (х100)
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tion an average tumor weight in tumor-bearing rats 
achieved 37.2 ± 9.5 g, in animals treated with entero-
sorbent — 27.2 ± 12.6 g, in animals treated with CP and 
CP + ES — 1.6 ± 2.5 and 1.3 ± 1.6 g respectively. At this 
day 2 from 7 tumor-bearing rats died, and 1 from 8 ani-
mals — in tumor + ES group. Tumor regression was not 
observed in both groups. In groups treated with CP and 
CP + ES none of animals died, while tumor absence was 
observed in 1 and 2 animals respectively. 
On day 22 morphological structure of tumor is typi-
cal for Guerin carcinoma (Fig. 6 a). In some tumors 
small area of necrosis and the presence of dystro-
phy-like altered cells were detected. Administration 
of enterosorbent did n’t significantly alter morphology 
picture of tumor (Fig. 6 b). Upon CP action necrotic 
regions of different sizes were formed in tumor tissue 
which were large enough in some animals (Fig. 6 c). 
Connective tissue is observed in moderate quantity 
as an appearance of separately placed fibroblast-like 
cells or their accumulations. ES introduction drastically 
alters morphological structure of tumor. In tumor one 
could observe large areas of newly generated con-
nective tissue which consists from connective fibers, 
fibroblasts, macrophages and large number of newly 
formed blood vessels (Fig. 6 d). In connective lining 
there were detected single tumor cells and single small 
regions of necrosis. Thus, instead of large necrotic area 
observed in tumor after CP treatment, the combined 
action of CP + ES resulted in the death of the majority 
of tumor cells and in appearance of connective tissue 
elements. The mechanisms and consequence of such 
events require the performance of additional studies. 
So, the obtained results have shown that potent an-
titoxic action of enterosorbents which are administrated 
1 h after intravenous administration of CP, is realized 
at the conditions of full preservation of its cytoxic activity. 
It is known that CP possesses a dose-dependent neph-
rotoxicity which is characterized by cumulative charac-
ter and is the main toxic factor which limits its high-dose 
regimen of use [22]. There is also a significant number 
of works devoted to altered gene expression in kidney 
tissue upon platinate action [22, 23]. The conditions 
of ES performance selected by us had allowed to pre-
vent severe toxic damage of tissues of kidney and 
other organs caused by toxic action of CP and tumor 
growth. Among many mechanisms of ES multifactor 
influence which have been discussed in a number of re-
lated studies [24–26], one should consider an evident 
role of adsorption of toxic products generated in the 
process of damage of normal and tumor cells as well 
as intermediate and final toxic metabolites of disturbed 
metabolism, what prevents their re-sorption and finally 
decreases metabolic and toxic load on excretion or-
gans, first of all — liver and kidneys. One of the most 
important properties of enterosorbents, especially 
carbon ones, is their ability to bind effectively bacterial 
endotoxins (BET) [27]. In the case of ES introduction 
into CP chemotherapy, this property of enterosorbents 
is of particular importance because of the fact that 
a
b
c
Fig. 4. Morphological structure of innate organs in Guerin 
carcinoma-bearing rats upon CP+ES treatment (х 200): a — ap-
pearance of hepatocytes with more basophilic cytoplasm and 
dense nucleus; b — renal tubules possess normal morphological 
structure; c — lymphoid follicle with large marginal zone in spleen
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Fig. 5. Dynamic of Guerin carcinoma growth
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BET synergistically promote CP nephrotoxicity: single 
administration of CP or BET to mice doesn’t cause renal 
dysfunction however their combined administration 
leads to the development of severe renal failure [28]. 
The obtained results allow conclude that ES at the 
regimen of daily use of active enterosorbents just 
1 h after CP administration possesses detoxicating 
potential sufficient for significant elimination of toxic 
effect of the cytostatic at the background of complete 
preservation of its antitumor activity. Apart from this, 
a drastic alteration of morphological picture of kid-
neys in tumor-bearing animals treated by combined 
CP-sorption therapy compared to that in animals 
treated with CP alone, allows to suggest that ES could 
be capable to affect gene expression in kidney tissues; 
such phenomenon has been registered earlier in the 
study of effect of carbon eneterosorbent administra-
tion on renal failure development modeled in rats [23]. 
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